Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, provides superior glycemic control and greater weight loss compared to semaglutide and other GLP-1 receptor agonists in patients with type 2 diabetes.
If you have Type 2 Diabetes and struggle with weight loss, Tirzepatide (brand name Tirzetta in Russia) is currently the most effective incretin-based treatment available. It works by mimicking two gut hormones (GIP and GLP-1) to improve blood sugar control and promote significant weight loss. Treatment starts with a low dose (2.5 mg weekly) to minimize side effects, then increases every 4 weeks up to 15 mg as needed. It is administered via a user-friendly auto-injector once a week alongside a calorie-controlled diet and exercise.
Tirzepatide is the most effective in terms of glycemic control and weight loss, followed by semaglutide and liraglutide.
Why this rating
Based on multiple Phase 3 clinical trials (SURPASS-2, SUSTAIN-3, etc.) cited in the review.
Source
Effects of incretin drugs on glycemic control and body weight
A. N. Levitskaya et al. · FOCUS Endocrinology · 2025
DOI 10.62751/2713-0177-2025-6-3-07
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →